Neurogene (NGNE) just unveiled an announcement.
Neurogene Inc. has revised its consulting agreement with Stuart Cobb Consulting Ltd., ensuring that Dr. Stuart Cobb, the company’s Chief Scientific Officer, receives a base annual fee of $440,000 with potential upward adjustments. Additionally, Dr. Cobb is eligible for an annual success fee of up to 40%, contingent on performance targets set and evaluated by the company’s board. In cases of termination without cause or resignation with good reason, Dr. Cobb could receive severance payments, including a lump sum equivalent to his annual fee, any owed success fees, and a pro-rated bonus, with special provisions if the termination occurs around a change in company control.
For detailed information about NGNE stock, go to TipRanks’ Stock Analysis page.
